CytomX Therapeutics (CTMX) Receivables (2014 - 2026)

CytomX Therapeutics has reported Receivables for 13 years, with the latest figure at $2.1 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables fell 24.86% year-over-year to $2.1 million; the trailing twelve-month figure through Mar 2026 stood at $2.1 million (down 24.86% YoY), and the FY2025 full-year result was $2.8 million, down 33.07% from the prior year.
• Receivables for Q1 2026 stood at $2.1 million, down from $2.8 million in the prior quarter.
• The five-year high for Receivables was $71.0 million in Q4 2022, with the low at $2.0 million in Q2 2022.
• Historically, Receivables has averaged $7.8 million across 5 years, with a median of $3.2 million in 2023.
• Annual changes were most pronounced in 2022 — Receivables surged 4364.53% — and 2023, when it slumped 93.62%.
• CytomX Therapeutics' Receivables stood at $71.0 million in 2022, then tumbled by 93.62% to $4.5 million in 2023, then dropped by 7.26% to $4.2 million in 2024, then sank by 33.07% to $2.8 million in 2025, then slipped by 23.71% to $2.1 million in 2026.
• The last three Receivables figures came in at $2.1 million (Q1 2026), $2.8 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.